DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies
| Agency | Dept. of the Army -- USAMRAA |
|---|---|
| Status | Posted |
| Opportunity number | HT942526ALSRPTDA |
| Posted date | 05/04/2026 |
| Application deadline | Sep 30, 2026 12:00:00 AM EDT |
| Award ceiling | none |
| Award floor | none |
| Estimated total funding | 12,000,000 |
| Expected number of awards | 6 |
| Assistance Listing (CFDA) | 12.420 |
| Description | Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints and pathophysiology. Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including |
| Agency contact | help@eBRAP.org |
| Official listing | https://www.grants.gov/search-results-detail/362196 |